[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cartesian Therapeutics Inc (RNAC)

Cartesian Therapeutics Inc (RNAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 221,540
  • Shares Outstanding, K 29,382
  • Annual Sales, $ 2,800 K
  • Annual Income, $ -130,300 K
  • EBIT $ -91 M
  • EBITDA $ -88 M
  • 60-Month Beta 0.58
  • Price/Sales 75.74
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 291.77% (+91.17%)
  • Historical Volatility 93.30%
  • IV Percentile 64%
  • IV Rank 38.29%
  • IV High 738.33% on 02/06/26
  • IV Low 14.64% on 09/08/25
  • Expected Move (DTE 18) 1.77 (23.45%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 48
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 873
  • Open Int (30-Day) 873
  • Expected Range 5.77 to 9.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.87
  • Number of Estimates 3
  • High Estimate $-0.76
  • Low Estimate $-0.95
  • Prior Year $0.50
  • Growth Rate Est. (year over year) -274.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.95 +26.72%
on 05/01/26
9.32 -19.14%
on 05/11/26
+1.07 (+16.54%)
since 04/29/26
3-Month
5.60 +34.64%
on 03/27/26
9.33 -19.19%
on 03/10/26
-0.05 (-0.66%)
since 02/27/26
52-Week
5.60 +34.64%
on 03/27/26
15.57 -51.57%
on 07/09/25
-1.55 (-17.05%)
since 05/28/25

Most Recent Stories

More News
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028 Financing strengthens Cartesian’s financial...

RNAC : 7.54 (+4.58%)
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases,...

RNAC : 7.54 (+4.58%)
Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases,...

RNAC : 7.54 (+4.58%)
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis  Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome initiated ...

RNAC : 7.54 (+4.58%)
Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune...

RNAC : 7.54 (+4.58%)
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update

Enrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate...

RNAC : 7.54 (+4.58%)
Cartesian Therapeutics to Participate in Upcoming Investor Conferences

FREDERICK, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases,...

RNAC : 7.54 (+4.58%)
Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases,...

RNAC : 7.54 (+4.58%)
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis  IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential...

RNAC : 7.54 (+4.58%)
Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases,...

RNAC : 7.54 (+4.58%)

Business Summary

Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company's lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy in Phase 2b clinical development for patients with...

See More

Key Turning Points

3rd Resistance Point 8.49
2nd Resistance Point 8.05
1st Resistance Point 7.79
Last Price 7.54
1st Support Level 7.09
2nd Support Level 6.65
3rd Support Level 6.39

See More

52-Week High 15.57
Fibonacci 61.8% 11.76
Fibonacci 50% 10.59
Fibonacci 38.2% 9.41
Last Price 7.54
52-Week Low 5.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.